Takahito Fukusumi

Dr. Takahito Fukusumi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NSNoah Sasa
Noah Sasa
TKToshihiro Kishikawa
Toshihiro Kishikawa
MMMasashi Mori
Masashi Mori
RIRie Ito
Rie Ito
YMYumie Mizoro
Yumie Mizoro
HIHidenori Inohara
Hidenori Inohara
Integration of human papillomavirus (HPV) into the host genome drives HPV-positive head and neck squamous cell carcinoma (HPV+ HNSCC). Whole-genome sequencing of 51 tumors revealed intratumor heterogeneity of HPV integration, with 44% of breakpoints subclonal, and a biased distribution of integration breakpoints across the HPV genome. Four HPV physical states were identified, with at least 49% of tumors progressing without integration. HPV integration was associated with APOBEC-induced broad genomic instability and focal genomic instability, including structural variants at integration sites. HPV+ HNSCCs exhibited almost no smoking-induced mutational signatures. Heterozygous loss of ataxia-telangiectasia mutated (ATM) was observed in 67% of tumors, with its downregulation confirmed by single-cell RNA sequencing and immunohistochemistry, suggesting ATM haploinsufficiency contributes to carcinogenesis. PI3K activation was the major oncogenic mutation, with JAK-STAT activation in tumors with clonal integration and NF-kappa B activation in those without. These findings provide valuable insights into HPV integration in HPV+ HNSCC.

1 June 2020 in Oral Oncology
Verified
Journal Article
Closed access
HCH. Cho
H. Cho
TKT. Kishikawa
T. Kishikawa
YTY. Tokita
Y. Tokita
MSM. Suzuki
M. Suzuki
NTN. Takemoto
N. Takemoto
HIH. Inohara
H. Inohara

15 August 2023 in Advances in Radiation Oncology
Verified
Journal Article
Open access
KTKeisuke Tamari
Keisuke Tamari
KMKazumasa Minami
Kazumasa Minami
STShotaro Tatekawa
Shotaro Tatekawa
YSYuji Seo
Yuji Seo
TFTakahito Fukusumi
Takahito Fukusumi
KOKazuhiko Ogawa
Kazuhiko Ogawa
Radiation therapy is widely used to treat head and neck squamous cell carcinoma (HNSCC). This study evaluated the association between circulating plasma programmed death-ligand 1 (PD-L1) and the outcomes of patients with HNSCC after radiation therapy. In this retrospective observational study, plasma samples of 76 patients with HNSCC who underwent radiation therapy from June 2019 to August 2021 were analyzed. These plasma samples were obtained before radiation therapy. The median follow-up was 32.5 months. Total and exosomal PD-L1 was measured by enzyme-linked immunosorbent assay and retrospectively analyzed for association with overall survival (OS), progression-free survival (PFS), and local control (LC). Prognostic factors among patients' characteristics and circulating PD-L1 in plasma were evaluated by univariate (log-rank test) and multivariate (Cox proportional hazards model) analyses. The median concentration of total PD-L1 in plasma was 115.1 pg/mL (95% CI, 114.7-137.9 pg/mL), and the median concentration of exosomal PD-L1 was 2.8 pg/mL (95% CI, 6.0-13.0 pg/mL). Univariate and multivariate analyses showed exosomal PD-L1 as a prognostic factor for PFS and LC. Patients with high exosomal PD-L1 in plasma had poor PFS and LC compared with those with low exosomal PD-L1, indicating that 1-year PFS was 79.2% versus 33.3% (P < .001) and 1-year LC was 87.3% versus 50.0% (P < .001) in patients with high and low exosomal PD-L1, respectively. However, exosomal PD-L1 in plasma had no significant effect on OS. Total PD-L1 in plasma did not correlate with PFS, LC, and OS. The pretreatment circulating exosomal PD-L1 in plasma of patients with HNSCC was a prognostic factor after radiation therapy.

31 March 2023
Verified
Other
Open access
TFTakahito Fukusumi
Takahito Fukusumi
TGTheresa Guo
Theresa Guo
ASAkihiro Sakai
Akihiro Sakai
MAMizuo Ando
Mizuo Ando
SRShuling Ren
Shuling Ren
JCJoseph A. Califano
Joseph A. Califano
Figure S1. The correlation of NOTCH pathway genes and the HES/HEY high group.

31 March 2023
Verified
Other
Open access
TFTakahito Fukusumi
Takahito Fukusumi
TGTheresa Guo
Theresa Guo
ASAkihiro Sakai
Akihiro Sakai
MAMizuo Ando
Mizuo Ando
SRShuling Ren
Shuling Ren
JCJoseph A. Califano
Joseph A. Califano
Table S1. HNSCC NOTCH mutation samples in TCGA

31 March 2023
Verified
Other
Open access
TFTakahito Fukusumi
Takahito Fukusumi
TGTheresa Guo
Theresa Guo
ASAkihiro Sakai
Akihiro Sakai
MAMizuo Ando
Mizuo Ando
SRShuling Ren
Shuling Ren
JCJoseph A. Califano
Joseph A. Califano
Figure S5. Comparison of HNSCC CSCs marker genes between NOTCH4, HEY1 high and low groups using the TCGA data set. ALDH1 expression in si-NOTCH4 and si-HEY1 cells.